AF
ATOS icon

Amalgamated Financial’s Atossa Therapeutics ATOS Stock Holding History

Amalgamated Financial’s Portfolio ATOS Stock Details ATOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$18K Buy
+968
New +$19.7K ﹤0.01% 2769

Other funds holding ATOS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Amalgamated Financial's ATOS Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Atossa Therapeutics (ATOS) in Q1 2022: 968 shares worth $18K. The stake represents ﹤0.01% of the portfolio and ranks #2769 among its holdings.

83 funds tracked by Wall St. Rank hold ATOS as of Q1 2022.

  • Amalgamated Financial held 968 shares of Atossa Therapeutics worth $18K as of Q1 2022.
  • Atossa Therapeutics was a new Amalgamated Financial position in Q1 2022.
  • Atossa Therapeutics made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #2769 holding.
  • 83 funds tracked by Wall St. Rank held Atossa Therapeutics as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.